These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21547266)

  • 21. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS; Gregory SA
    Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
    Osterborg A; Karlsson C; Lundin J
    Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Successful treatment with rituximab for autoimmune hemolytic anemia associated with chronic lymphocytic leukemia].
    Tanaka Y; Ito Y; Yoshizawa S; Fujimoto H; Gotoh M; Tauchi T; Kimura Y; Ohyashiki K
    Rinsho Ketsueki; 2013 Feb; 54(2):229-31. PubMed ID: 23470833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas.
    Hauswirth AW; Skrabs C; Schützinger C; Gaiger A; Lechner K; Jäger U
    Leuk Lymphoma; 2007 Jun; 48(6):1139-49. PubMed ID: 17577777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
    Sawas A; Farber CM; Schreeder MT; Khalil MY; Mahadevan D; Deng C; Amengual JE; Nikolinakos PG; Kolesar JM; Kuhn JG; Sportelli P; Miskin HP; O'Connor OA
    Br J Haematol; 2017 Apr; 177(2):243-253. PubMed ID: 28220479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
    D'Arena G; Cascavilla N
    Leuk Lymphoma; 2007 Jun; 48(6):1072-80. PubMed ID: 17577769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine-induced hemolytic anemia: successful treatment by rituximab.
    Paydas S
    Hematol J; 2004; 5(1):81-3. PubMed ID: 14745435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-specific complications of chronic lymphocytic leukemia.
    Dearden C
    Hematology Am Soc Hematol Educ Program; 2008; ():450-6. PubMed ID: 19074125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autoimmune hemolytic anemia].
    Berentsen S; Sundic T; Hervig T; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2009 Nov; 129(21):2226-31. PubMed ID: 19898570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
    Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
    Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases.
    Cervetti G; Mechelli S; Riccioni R; Galimberti S; Caracciolo F; Petrini M
    Clin Exp Rheumatol; 2005; 23(6):877-80. PubMed ID: 16396708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab.
    Lidický O; Klener P; Machová D; Vočková P; Pokorná E; Helman K; Mavis C; Janoušková O; Etrych T
    J Control Release; 2020 Dec; 328():160-170. PubMed ID: 32860930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
    Byrd JC; Kitada S; Flinn IW; Aron JL; Pearson M; Lucas D; Reed JC
    Blood; 2002 Feb; 99(3):1038-43. PubMed ID: 11807010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Yang H; Rosove MH; Figlin RA
    Am J Hematol; 1999 Dec; 62(4):247-50. PubMed ID: 10589082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
    Rastetter W; Molina A; White CA
    Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
    Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
    Front Immunol; 2020; 11():584509. PubMed ID: 33329558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Zhuang Y; Xu W; Shen Y; Li J
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):347-52. PubMed ID: 21030347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.